Navigation Links
Transparency lacking in clinical trials, BU study finds
Date:7/15/2014

A significant percentage of completed drug clinical trials, especially those funded by industry, are not disclosed to the public, years after being completeda trend that "threatens the validity of the clinical research literature in the U.S.," according to a study led by a Boston University School of Public Health (BUSPH) researcher.

The study, published in the journal PLOS ONE, found that close to 30 percent of 400 randomly selected clinical trials completed in 2008 had not resulted, four years later, in either publication in a journal or the posting of results to the ClinicalTrials.gov (CTG) web site.

Studies that were funded solely by industry, or that involved smaller sample sizes, were less likely to be published, the research shows.

The study's lead author, Dr. Christopher Gill, director of BUSPH's Pharmaceuticals Program and an associate professor of global health, said the review raises ethical, as well as scientific, problems.

"Individuals who volunteer for clinical trials often do so out of a sense of altruism," said Gill, a researcher with BU's Center for Global Health and Development. "I can imagine that many would be dismayed to learn that the results of a study that they participated in, that they took physical risks for, might never generate results known beyond the company that sponsored the trial.

"Science learns from mistakes, as well as successes," he said. "If we only learn about the scientific success stories, we are really only seeing part of the picture."

Gill and a former student, Hiroki Saito, found that 118 of the 400 clinical trials did not result in publication within four years of completion. The median length of time from completion to public disclosure was 602 days.

Among industry-funded studies, rates of posting to the CTG site were high for phase 3 or 4 studies, but extremely low for phase 2 studies.

"As an overall synthesis, these findings provide strong evidence of reporting bias," Gill and Saito wrote. They said the associations between publication or posting rates and funding sources "merit further consideration, and may reflect differing motivations" among researchers.

Among academics working under a "publish or perish" model, and who represent the majority of non-industry funded studies, the study phase "may be less critical than the need to publish research findings in journals," Gill and Saito said. By contrast, the pharmaceutical industry may publish more results for products that have advanced to phase 3 or beyond and are perceived to be commercially viable.

Gill and Saito suggested that regulatory requirements could be driving the differences in rates of posting results to the CTG. Among industry-funded, phase 3 or 4 studies, the majority of researchers posted their results at about one year from completioncoinciding closely with a one-year deadline established in 2007 by the Food and Drug Administration Amendments Act (FDAAA).

Regardless of the reasons, Gill and Saito said, transparency in clinical trials is "an essential public health good. The public must be informed if the premise of a clinical trial was confirmed or invalidated, and expects that, once a study involving human subjects is completed, its results will be published in the medical literature or posted to some other open-access platform."

They said that in order to maintain the public's faith in clinical research, and to protect the fidelity of the scientific literature, "it is essential that the research community unite around the common goal of maximizing transparency. "

In 2012, Gill reported that among US-based, industry-funded phase 2 or higher clinical studies, less than 25 percent had posted their results to CTG within a year of completion. Another study found that, among National Institutes of Health-funded trials, 32 percent remained unpublished after the median follow-up of 51 months from completion.


'/>"/>

Contact: Christopher Gill
cgill@bu.edu
617-571-6370
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. BMJ urged to widen its approach to transparency
2. Global Fermentation Chemicals Market Research Report: Transparency Market Research
3. Global Teleradiology Market Is Expected to Reach USD 3.78 Billion in 2019: Transparency Market Research
4. Global Breath Analyzers Market is Expected to Reach USD 4.5 Billion in 2019: Transparency Market Research
5. Global Hernia Repair Devices Market is Expected to Reach USD5.9 Billion in 2019: Transparency Market Research
6. URAC and The Leapfrog Group Announce Winners of the 2013 Hospital Website Transparency Awards Program
7. Global Medical Imaging Equipment Market Is Expected to Reach USD 35.35 Billion in 2019: Transparency Market Research
8. Global Neurology Devices Market is Expected to Reach USD 13.6 Billion in 2019: Transparency Market Research
9. Global Forensic Technologies Market is Expected to Reach USD 17.7 Billion in 2019: Transparency Market Research
10. Patients “Self-Refer” To Practices With Health Care Transparency Tools
11. Global Atrial Fibrillation Market is Expected to Reach USD 14.8 Billion in 2019: Transparency Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2019)... ... July 18, 2019 , ... NeoTract, a wholly owned subsidiary ... urology, today announced that Garrett Matsunaga, MD, Skyline Urology in Torrance, CA has ... Matsunaga has achieved a high level of training and experience with the UroLift® ...
(Date:7/18/2019)... LA JOLLA, Calif. (PRWEB) , ... July 18, 2019 , ... ... insight into their future children, announces a new publication titled, “ Accurate Fetal Sex ... Pregnancy & Child Birth. In the study, DNA blood samples were collected from 108 ...
(Date:7/17/2019)... Calif. (PRWEB) , ... July 17, 2019 , ... ... enterprise-wide solutions to health plans participating in Medicare Advantage, Medicaid, and Marketplace programs ... solution for Providers featuring Electronic Health Records (EHR) integration at the ...
(Date:7/17/2019)... ... July 17, 2019 , ... This past Saturday, Monarch Dental® ... Foundation . Over 50 underserved patients were welcomed at the Mesquite office to receive ... the summer season. Individuals were referred to the event through local nonprofit organizations such ...
(Date:7/17/2019)... ... July 17, 2019 , ... Women’s Excellence is pleased to announce a new office opening ... The new offices resides on the corner of Turrill Road and South Lapeer Roads, ... thrilled about the opening of our new office in Lapeer and the ability to service ...
Breaking Medicine News(10 mins):
(Date:7/18/2019)... ... July 18, 2019 , ... ... solutions for over 20 years, announced today it is moving into new corporate ... , “We are thrilled to be moving into the new office which ...
(Date:7/17/2019)... NY (PRWEB) , ... July 17, 2019 , ... Chlorophyll ... served at the United Nations for International Yoga Day 2019. , International Day ... solstice, June 21st. The day was declared unanimously by the United Nations General Assembly. ...
(Date:7/17/2019)... ... July 17, 2019 , ... Halcyon, one of the ... payment processor of record. , As a result of the partnership, funeral ... can now also accept and process payments through it, securely and easily. ...
Breaking Medicine Technology: